as 12-20-2024 3:42pm EST
Sanara MedTech Inc is a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the chronic and surgical wound and skincare markets. Its portfolio of products and services allows it to deliver comprehensive wound and skincare solutions for patients in all care settings, including acute and post-acute. Its surgical wound care products are CellerateRX Surgical Activated Collagen. Its chronic wound care products are HYCOL Hydrolyzed Collagen, BIAKOS Skin and Wound Cleanser, and BIAKOS Skin and Wound Gel.
Founded: | 1982 | Country: | United States |
Employees: | N/A | City: | FORT WORTH |
Market Cap: | 288.2M | IPO Year: | N/A |
Target Price: | $44.00 | AVG Volume (30 days): | 36.4K |
Analyst Decision: | Buy | Number of Analysts: | 1 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -0.99 | EPS Growth: | N/A |
52 Week Low/High: | $26.00 - $43.25 | Next Earning Date: | 11-12-2024 |
Revenue: | $78,056,873 | Revenue Growth: | 24.66% |
Revenue Growth (this year): | 29.95% | Revenue Growth (next year): | 19.68% |
SMTI Breaking Stock News: Dive into SMTI Ticker-Specific Updates for Smart Investing
GlobeNewswire
a month ago
Simply Wall St.
a month ago
Simply Wall St.
a month ago
GuruFocus.com
a month ago
GlobeNewswire
a month ago
GuruFocus.com
a month ago
Simply Wall St.
2 months ago
GlobeNewswire
2 months ago
The information presented on this page, "SMTI Sanara MedTech Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.